Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gadoxetate Sodium MRI for Aggressive Prostate Cancer
NCT03960788Phase 1Unknown
- Sponsor
- University of Cincinnati
- Start
- Jan 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gadoxetate disodium, sponsored by University of Cincinnati. Primary endpoint: Comparison of Gadoxetate Sodium to gadolinium in effectiveness of identification of prostate cancer as measured by contrast enhancement ratios at 3 weeks. Status: unknown.
02
Drugs
gadoxetate disodium
Beyond the preview
Go deeper on NCT03960788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03960788.